FDA Wants Comments On Generics Law, But Not Declaratory Judgments
Executive Summary
FDA is opening a docket on implementing the changes to Waxman/Hatch made under the Medicare Rx law enacted in 2003
You may also be interested in...
Multiple 30-Month Stays Remain Possible Under Waxman/Hatch Reforms
Multiple 30-month stays on abbreviated new drug applications are still an option in some cases, an FDA 1draft guidance says
Multiple 30-Month Stays Remain Possible Under Waxman/Hatch Reforms
Multiple 30-month stays on abbreviated new drug applications are still an option in some cases, an FDA 1draft guidance says
Waxman/Hatch Reforms Still Allow Multiple 30-Month Stays, PhRMA Says
FDA should "clarify" that Waxman/Hatch reforms included in the Medicare law still allow for more than one 30-month stay on ANDA approval in some cases, the Pharmaceutical Research & Manufacturers of America said in comments submitted to FDA's generic drugs docket